Mitogen-activated protein kinases (MAPKs) regulate diverse cellular programs including embryogenesis, proliferation, differentiation and apoptosis based on cues derived from the cell surface and the metabolic state and environment of the cell. In mammals, there are more than a dozen MAPK genes. The best known are the extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinase (JNK(1-3)) and p38(a, b, c and d) families. ERK3, ERK5 and ERK7 are other MAPKs that have distinct regulation and functions. MAPK cascades consist of a core of three protein kinases. Despite the apparently simple architecture of this pathway, these enzymes are capable of responding to a bewildering number of stimuli to produce exquisitely specific cellular outcomes. These responses depend on the kinetics of their activation and inactivation, the subcellular localization of the kinases, the complexes in which they act, and the availability of substrates. Fine-tuning of cascade activity can occur through modulatory inputs to cascade component from the primary kinases to the scaffolding accessory proteins. Here, we describe some of the properties of the three major MAPK pathways and discuss how these properties govern pathway regulation and activity.
The protein kinase cascade Extracellular signal-regulated kinase 1 (ERK1) and ERK2 were identified as growth factor-stimulated protein kinases phosphorylating microtubule-associated protein-2 (MAP-2) and myelin basic protein (MBP) 20 years ago. They are 43 and 41 kDa, share 83% identity, and are ubiquitously expressed. ERK1/2 phosphorylate the protein kinases p90 ribosomal S6 kinase (RSK), mitogen and stress activated kinase (MSK) and MAPK interacting kinase (MNK) proteins involved in cell attachment and migration, including paxillin, focal adhesion kinase and calpain; and the transcription factors Elk1, c-Fos, c-Myc and Ets domain factors, among many others. ERK1/2 are activated to varying extents by growth factors, serum, phorbol esters and ligands for heterotrimeric G protein-coupled receptors, cytokines, transforming growth factors, osmotic and other cell stresses, and microtubule depolymerization. Activation of ERK1/2 is involved in many cellular responses such as cell motility, proliferation, differentiation and survival (Lewis et al., 1998; Chen et al., 2001; Johnson and Lapadat, 2002; Yoon and Seger, 2006) .
The mitogen-activated protein kinase (MAPK) kinases (MAP2Ks) MEK1 and -2 are the upstream dualspecificity ERK1/2 kinases that phosphorylate tyrosine and threonine residues in the ERK1/2 activation loops ( Figure 1 ). The MAP2K kinases or MAP3Ks phosphorylate two serine residues or a serine and a threonine residue in the activation loop of the MAP2Ks to activate them. In the ERK1/2 pathway Raf isoforms are the primary MAP3Ks. Mos, Tpl2, and perhaps other MAP3Ks are utilized in a more restricted cell type and stimulus-specific manner.
Raf isoforms, A-Raf, B-Raf and C-Raf or Raf-1, are the best-studied MAP3Ks and those that most frequently and selectively regulate the ERK1/2 pathway. Raf is activated by a combination of binding of small G proteins of the Ras family to its N-terminus and phosphorylation. Raf-1 was initially identified as the MAP3K in the ERK1/2 pathway through its ability to activate MEK1 and shortly thereafter as the effector through which Ras controls the cascade (Rapp et al., 2006) .
Mos is the MAP3K utilized during oocyte maturation. Mos activates ERK1/2 in Xenopus cell-free extracts and intact oocytes. Activation of the pathway requires translation of Mos, distinguishing its regulation from that of other MAP3Ks in this pathway. In immature oocytes, Mos mRNA is present but not translated into protein. In response to steroid receptor stimulation, an increase in polyadenylation of Mos transcript is observed. This increases Mos protein production, which activates MEK1 and subsequently ERK1/2. Active ERK1/2 positively influence Mos protein production and amplify activation of the pathway leading to CDK1 activation and germinal vesicle breakdown. This germcell-specific mechanism of ERK1/2 activation has been known for a number of years, but factors that regulate this cascade have not been identified. The scaffold paxillin, often found in focal adhesions, is required for Mos-mediated ERK2 activation in Xenopus oocytes (Rasar et al., 2006) . Activated ERK2 positively impacts Mos production at least in part by phosphorylation of paxillin, which is indirectly or directly due to ERK2. The ERK2-dependent phosphorylation of paxillin accelerates Mos protein production thereby driving meiotic progression. Paxillin may regulate Mos via effects on processing or translation of the mRNA and on protein stability.
The MAP3K Tpl2, related to yeast protein kinases in the mating pathway, was originally identified as the Cot protooncogene. When overexpressed, it activates ERK1/2, c-Jun N-terminal kinase (JNK), p38 and ERK5 via its ability to phosphorylate and activate MAP2Ks upstream of these MAPKs (Salmeron et al., 1996; Chiariello et al., 2000) . The signaling role of Tpl2 depends on both the cell type and stimulus. Studies in Tpl2 knockout mice have shown that Tpl2 is required for ERK1/2 but not for JNK activation in lipopolysaccharide (LPS)-stimulated macrophages and B cells (Dumitru et al., 2000) . On the other hand, Tpl2 is required for the activation of ERK1/2 and JNK by tumor necrosis factor-alpha (TNF-a) in mouse embryonic fibroblasts (MEFs) (Das et al., 2005) . Additionally, in macrophages and B cells, Tpl2 is an essential mediator of ERK1/2 activation in response to diverse Toll-like receptor (TLR) signals (Cho and Tsichlis, 2005; Babu et al., 2006) . Activation of Tpl2 is dependent on several steps. In contrast to Raf and Mos, Tpl2 is stabilized by association with p105 of the nuclear factorkappa B (NF-kB) pathway. Its release from p105 is required to activate MAPK cascades (Kolch, 2005) .
Much of what we know currently about ligandinduced activation of MAPK cascades has been inferred from single ligand treatments in specific cell types. However, in vivo, the cell is sensing hundreds of different cues at any given time. Several efforts have been undertaken to assess responses of cells to combinations of ligands and to elucidate how responses to multiple stimuli are integrated to produce discrete outcomes. For example, depending on the cell type and stimulating ligand, cyclic AMP (cAMP) can either inhibit or activate ERK1/2. Phorbol ester-induced activation of ERK1/2 is inhibited by stimulation of cAMP accumulation, whereas epidermal growth factor (EGF) is capable of activating ERK1/2 independent of changes in cAMP concentration (Pearson et al., 2006) . Aberrant interactions between the ERK1/2 and cAMP pathways are involved in diseases ranging from polycystic kidney disease to melanoma (Yamaguchi et al., 2003; Rapp et al., 2006) . cAMP also differentially regulates the MAPK ERK5 in a cell-type-and context-dependent manner. cAMP inhibits EGF-induced ERK5 activation and subsequently decreases cell proliferation. cAMPdependent protein kinase phosphorylates MEKK2, a key MAP3K upstream of ERK5 activation (see Johnson, this issue), thus inhibiting activation of this cascade by growth factors (Pearson et al., 2006) . Thus, it appears that cells with elevated cAMP are more refractory to growth factor stimulation owing to some re-wiring of signaling interactions upstream of MAP3Ks.
Regulation of ERK1/2 interactions via docking motifs Docking motifs in MAPKs, as well as reciprocal interaction motifs in regulators and substrates, are critical specificity determinants in MAPK signaling (Table 1) . A motif recognized by most MAPKs is the docking or D motif. These motifs are found in substrates as well as MAP2Ks, phosphatases and scaffolds. Frequently, these motifs appear N-terminus to the typical serine/threonine-proline phosphorylation site preferred by ERK1/2 and are characterized by a cluster of positively charged residues with two or more nearby hydrophobic residues (Sharrocks et al., 2000; Tanoue et al., 2000) . In addition to the D motif, the Figure 1 MAPK cascades. Illustration of the three-tiered MAPK cascades for ERK, JNK and p38 family members.
Differential regulation and properties of MAPKs M Raman et al docking site for ERK and FXFP (DEF, also known as FXF for its amino-acid specificity) motif has been identified in many ERK1/2 substrates, such as Elk-1, SAP-1 and c-Fos, and in the scaffold kinase suppressor of Ras (KSR) (Jacobs et al., 1999) . The DEF or FXF motif typically follows the phospho-acceptor site in the primary sequence of interactors. D and FXF motifs may act synergistically to facilitate MAPK interaction. D motifs bind to conserved C-terminal common docking (CD) sites identified in ERK1/2 and other MAPKs. An ERK docking (ED) site was identified and an understanding of mechanisms by which binding proteins discriminate between ERK1/2 and p38 is being developed from crystallographic and mapping studies Zhou et al., 2006b) . Interaction motifs have also been identified in upstream kinases. A conserved docking or DVD site has been identified in the mammalian MAP2Ks, MEK1, MEK4/7 and MEK3/6, which couple to the three major MAPK cascades. The DVD site lies within a 20-residue sequence C terminus to the MAP2K catalytic core. This motif binds to certain upstream MAP3Ks, including MEKK4, ASK1, TAK1, TAO2, MEKK1 and Raf-1 (Takekawa et al., 2005) .
Regulation of signaling by scaffolds
Assembly of MAPK cascade components by scaffolding proteins allows for efficient phosphorylation and pathway activation. The close proximity of components makes it possible to integrate incoming signals in localized microenvironments (Elion, 2001; Morrison and Davis, 2003; Kolch, 2005) . Scaffold proteins recruit different components of a specific pathway simultaneously. The first MAPK scaffold discovered was Ste5p, which assembles the Ste11p-Ste7p-Fus3p MAPK module of the Saccharomyces cerevisiae pheromone mating pathway, and couples this cascade to cytoskeletal components of the cell.
Orthologs of Ste5p have not been identified in higher eukaryotes. However, a number of binding proteins that may serve as scaffolds for the ERK1/2 pathway have been identified. These include KSR, MEK partner-1 (MP1), b-arrestins, similar expression to FGF (Sef) and IQGAP (Morrison and Davis, 2003) .
KSR was identified in Ras-dependent large-scale genetic screens in Drosophila melanogaster and Caenorhabditis elegans (Morrison and Davis, 2003) . Although it has a protein kinase domain, it lacks a key catalytic lysine residue and is thus inactive. KSR directly interacts with Raf-1, MEK1/2 and ERK1/2. Some fractions of MEK1/2 are stably associated with KSR in quiescent cells. Upon Ras activation, KSR translocates with MEK1/2 to the plasma membrane, which brings MEK1/2 in close proximity to its activator Raf-1 and downstream effectors ERK1/2. These interactions lead to the formation of a Raf/MEK/ERK complex, thereby facilitating the activation of ERK1/2. Many other proteins bind to KSR, including Hsp90, G protein g subunits, the protein kinase c-TAK1 and 14-3-3 (Morrison and Davis, 2003) .
The means by which other scaffolds regulate ERK1/2 are less clear. Some scaffolds such as MP1 appear to interact with only two of the ERK1/2 pathway components. MP1 localizes specifically to endosomes by interacting with the adaptor protein p14, where it promotes the formation and activation of ERK complexes in response to EGF (Teis et al., 2002) . b-Arrestins 1 and 2 function as scaffolds to enhance Raf-1 and MEK-dependent activation of ERK1/2, and direct the activated ERK1/2 into endosomal vesicles (Luttrell et al., 2001) . Sef acts as a spatial regulator for ERK1/ 2 signaling by inhibiting active ERK1/2 actions in the nucleus (Torii et al., 2004) . Sef colocalizes with activated ERK as well as activated MEK mainly on the Golgi apparatus in stimulated cells. Thus, Sef is thought to block ERK1/2 signaling to the nucleus by retaining them in cytoplasmic complexes. IQGAP1 binds MEK1/2 and has been suggested to assemble an activated ERK/MAPK module at the site of localized actin polymerization (Roy et al., 2004; Kolch, 2005) . Ligand-and cell context-dependent mechanisms that favor ERK1/2 localization with specific scaffolds are not well defined.
Regulation by protein phosphatases
MAPKs, MAP2Ks and MAP3Ks are all activated by phosphorylation. Inhibition of MAP2Ks and MAP3Ks and modulation of their functions through regulated protein-protein interactions also occur through phosphorylation. Thus, phosphoprotein phosphatases are positioned to impact all aspects of MAPK cascade function both positively and negatively. Dephosphorylation of Differential regulation and properties of MAPKs M Raman et al either the phospho-threonine or the phospho-tyrosine residue in the activation loop of ERK1/2 causes a substantial decrease their activity. These events can be controlled by phosphoprotein phosphatases that are classified in three groups based on preference for dephosphorylating phospho-tyrosine, phospho-serine/ threonine, or both types of phosphoresidue (dualspecificity phosphatase (DSP)). The DSPs share a similar domain architecture and sequence with the tyrosine phosphatases, and contain a conserved signature motif HCX 5 R. They display distinct substrate specificities for different MAPKs in vitro and in vivo.
The DSPs that act with selectivity on MAPKs are known as MAPK phosphatases (MKPs; see Keyse article, this volume). These enzymes have a variety of subcellular localizations and regulatory mechanisms. Structural analysis of the interaction between MKP3 and ERK2 has shed light on the stringent substrate selectivity of MKP3. Multiple interactions between MKP3 and ERK2 have been inferred from hydrogen/ deuterium exchange mass spectrometry. Two regions on MKP3 bind to the CD site on ERK2. Simultaneous interactions are also made between MKP3 and the activation loop of ERK2 that optimally position MKP3 to dephosphorylate the kinase (Zhang et al., 2003; Zhou et al., 2006a) . This bimodal scheme of binding may be one determinant that distinguishes MKPs that are specific for a particular MAPK from those that appear to dephosphorylate all MAPK family members. Interactions of a number of these phosphatases with ERK1/2 can be modulated via phosphorylation of the phosphatase in the vicinity of its ERK1/2 interaction domain. For example, the interaction of the hematopoietic protein tyrosine phosphatase (He-PTP) with and subsequent dephosphorylation of ERK1/2 is inhibited by PKA-mediated phosphorylation of serine 23 in the kinase interaction motif, another name for the D motif, on He-PTP (Saxena and Mustelin, 2000) . Striatalenriched protein tyrosine phosphatase (STEP) activity is also regulated by phosphorylation. This phosphatase is phosphorylated and inactive in striatal neurons. Upon N-methyl D-aspartate receptor stimulation, STEP is dephosphorylated by calcineurin and interacts with and dephosphorylates ERK1/2 (Paul et al., 2002) . Hence phosphorylation of these proteins in and around MAPK docking motifs is another means of regulating their activity.
Protein phosphatase 2A (PP2A) is an important regulator of the ERK1/2 MAPK cascade. PP2A binds in a growth factor-dependent manner to the KSR scaffold and dephosphorylates both KSR and Raf1 on inhibitory sites. Dephosphorylation of the inhibitory sites allows Raf1 to be activated by Ras. Therefore, PP2A activity is required for activation of the pathway (Dougherty et al., 2005) . PP2A action is modulated by targeting its catalytic or C subunit to specific cellular compartments via multiple regulatory B subunits. A Ba subunit binds to KSR, and it was shown that the B56 family of subunits specifically targets PP2A to ERK1/2 through the immediate early gene IEX-1. Dephosphorylation of ERK1/2 is inhibited by the ERK1/2 substrate IEX-1, which binds B56 and promotes ERK1/2 phosphorylation of the B56 subunit. The phosphorylated form of B56 disassociates from the PP2A catalytic subunit (Letourneux et al., 2006) . Other B family members may work in a similar manner by targeting PP2A to MAPKs in a ligand or context-dependent manner. Calcineurin (PP2B) has also been implicated in the activation of ERK1/2 although the mode of action may be more indirect in that it may act at steps upstream of ERK1/2 (Paul et al., 2002; Arnette et al., 2003) .
Other post-translational modifications affecting activation of MAPKs Certain bacterial effector proteins, including the Yersinia pestis effector YopJ, impact MAPK pathway activity (Orth et al., 1999) . YopJ blocks activation of the ERK1/2, JNK and p38 MAPK cascades. MAP2Ks were identified as the sites of action of YopJ. The elucidation of the mechanism of YopJ action revealed a novel covalent modification in mammalian cells (Mukherjee et al., 2006) . Using a combination of in vitro reconstitution and mass spectrometry, YopJ was found to catalyse the acetylation of the serine/threonine residues in MAP2K activation loops, thereby preventing their phosphorylation and activation by MAP3Ks. The discovery of these modifications in MAP2Ks suggests that other heretofore unrecognized modifications of MAPK cascade components will be identified. In addition, acetylation of phosphorylatable residues may be employed in other enzymes and pathways to restrict phospho-regulation.
Splice variants of ERK1/2
ERK1b is a 46 kDa alternatively spliced form of ERK1 found in rodents (Yung et al., 2001) . ERK1b is identical in sequence to ERK1, but contains an insertion in the C-terminus of the protein kinase that bears no sequence homology to other known proteins. This insertion disrupts the CD site in ERK1b and may explain the reduced sensitivity of this variant to phosphatases such as PTP-SL and MKP3 (Yung et al., 2001) . The kinase is activated in a similar manner to ERK1/2 in response to EGF and NGF, but unlike ERK1/2, is more robustly activated by osmotic stress. ERK1b is activated by MEK1 and phosphorylates known ERK1/2 substrates, but appears to interact poorly MEK1. Although the precise role of ERK1b is unknown, its reduced sensitivity to phosphatases may allow it to signal in a sustained manner in the cytosol when ERK1/2 is no longer active.
Owing to sequence variation in the intronic regions involved in the splicing reaction, this spliced form of human ERK1, called ERK1c, has a deletion and an insertion and is only 42 kDa. ERK1c is apparently monoubiquitinated under conditions of high cell density and this modified form is enriched in the Golgi where ERK1c is involved in Golgi fragmentation during late G2 and mitosis (Jesch et al., 2001; Shaul and Seger, 2006) . The site of ubiquitination and how this modification is regulated is unknown at present. Given the ER and Golgi enrichment of pools of H-and K-Ras, it may Differential regulation and properties of MAPKs M Raman et al be that Golgi targeting of ERK1c allows it to be specifically regulated by these internal membrane associated forms of Ras. Because the Golgi/ER forms of Ras are associated with sustained MAPK signaling, this may explain the different kinetics of activation of ERK1/2 versus ERK1c by specific stimuli. Other ERK1 and ERK2 splice variants likely exist.
Subcellular localization ERK1/2 are distributed throughout the cell. They are associated with plasma membrane receptors and transporters. Components of the ERK1/2 cascade have been found in membrane compartments associated with lipid rafts and caveolae (Furuchi and Anderson, 1998 ). As noted above, the scaffolds MP1 and Sef direct ERK1/2 to endosomes and Golgi, respectively.
As much as half of ERK1/2 is bound to cytoplasmic microtubules, where they impact polymerization dynamics (Reszka et al., 1995) . ERK1/2 are required for cell motility and are found at adherens junctions and focal adhesions, sites of cell-cell and cell-matrix contact. In addition to its role in oocyte maturation, paxillin in focal adhesions is reported to bind to ERK1/2, Raf and MEK in response to hepatocyte growth factor (HGF). ERK1/2 phosphorylation of paxillin is required for subsequent Rac activation and is thought to be important for cell migration (Ishibe et al., 2004) .
Many studies have demonstrated that activation of ERK1/2 by growth factors and other ligands induces their translocation to the nucleus. This relocalization allows ERK1/2 access to nuclear transcription factors and other nuclear proteins that are then phosphorylated and/or stabilized to bring about relevant changes in gene expression. The distribution of ERK1/2 is tightly regulated by multiple means. In addition to the microtubule cytoskeleton, MEK1 is considered to be one of the most important regulators of ERK1/2 localization. MEK1 binds to ERK1/2 and harbors a strong nuclear export sequence (NES). Thus, it retains unphosphorylated ERK1/2 in the cytosol by binding to it and may escalate nuclear export of the unphosphorylated kinases . Overexpression of ERK1/2 in cells frequently drives them into the nucleus, presumably by overwhelming cytosolic binding sites (Rubinfeld et al., 1999) .
In addition to its interaction with the CD site through its D motif, MEK1 binds to ERK1/2 via the MAPK insert, a region utilized by another ERK1/2 binding partner, protein enriched in astrocytes (PEA-15) (Tanoue et al., 2000; Robinson et al., 2002; Whitehurst et al., 2004) . This protein also inhibits the nuclear translocation of ERK1/2 (Formstecher et al., 2001; Whitehurst et al., 2004) .
The import of active and inactive ERK1/2 may occur by different mechanisms. Activated ERK2 is imported into the nucleus via an active transport process (Ranganathan et al., 2006) . On the other hand, both active and inactive ERK2 can be imported into the nucleus via an energy-and transport factor-independent, passive process (Matsubayashi et al., 2001; Whitehurst et al., 2002; Ranganathan et al., 2006) . This involves binding of ERK1/2 to the FXF repeats of nucleoporins that comprise the nuclear pore complex (Matsubayashi et al., 2001; Whitehurst et al., 2002) . In primary human fibroblasts, the extent of nuclear import of active ERK1/2 is regulated in a stimulus-dependent manner. Many studies have shown that the localization of ERK1/2 induced by ligands affects phenotypic output. One way in which the core ERK1/2 signaling cascade can produce distinct responses is through ligand-dependent restriction of the active components to certain subcellular compartments.
c-Jun N-terminal kinases/stress-activated protein kinases (JNK/SAPK) Introduction JNK/SAPK was identified as a cycloheximide-activated MAP-2 kinase and as an activity that could be affinitypurified on c-Jun bound to beads. Three distinct genes encode JNK/SAPKs: JNK1/SAPKb, JNK2/SAPKa and JNK3/SAPKg. The proteins are greater than 85% identical and exist as 10 or more spliced forms with molecular weights ranging from 46 to 55 kDa (Kyriakis and Avruch, 2001; Johnson and Lapadat, 2002) . JNK1 and JNK2 are ubiquitous, whereas JNK3 is relatively restricted to brain. In vitro and gene disruption studies demonstrate functional differences among JNK isoforms. JNK1 is the major c-Jun kinase after stimulation, and JNK2 is preferentially bound to c-Jun in unstimulated cells and contributes to c-Jun degradation by a ubiquitin-dependent mechanism. JNK2 also regulates the stability of JunB, c-Myc and ATF2 (Alarcon-Vargas and Ronai, 2004; Sabapathy et al., 2004) .
JNK/SAPKs are activated in response to inflammatory cytokines; environmental stresses, such as heat shock, ionizing radiation, oxidant stress and DNA damage; DNA and protein synthesis inhibition; and growth factors (Kyriakis and Avruch, 2001) . JNKs phosphorylate transcription factors c-Jun, ATF-2, p53, Elk-1, and nuclear factor of activated T cells (NFAT), which in turn regulate the expression of specific sets of genes to mediate cell proliferation, differentiation or apoptosis. JNK proteins are involved in cytokine production, the inflammatory response, stress-induced and developmentally programmed apoptosis, actin reorganization, cell transformation and metabolism (Chen et al., 2001) . In response to stimulation by insulin, JNK associates with insulin receptor substrate 1 (IRS-1) and phosphorylates it on serine 307, uncoupling IRS-1 from insulin signaling. Thus, JNK appears to serve a dual function as a heterologous inhibitor of insulin action during acute and chronic inflammation and as a feedback inhibitor during insulin stimulation (Aguirre et al., 2000) . This action of JNK on insulin signaling may contribute to the substantial role of JNK in obesity (Hirosumi et al., 2002) .
The predominant MAP2Ks upstream of JNK are MEK4 (MKK4) and MEK7 (MKK7). In certain settings these two proteins may also activate the p38
Differential regulation and properties of MAPKs M Raman et al pathway, consistent with the small, but reproducible differences in activation of p38 in MEK4 knock-out cells (Ganiatsas et al., 1998) . MEK4/MEK7 phosphorylate and activate JNK on the TPY motif within the activation loop with the preference of MEK4 for tyrosine and of MEK7 for threonine. It was suggested that MEK4 and MEK7 activate JNKs synergistically (Lawler et al., 1998) . To add to the complexity at this level of the pathway, splice variants of MEK7 exhibit differences in affinity and ability to activate JNK MAPKs (Tournier et al., 1999) . These two MAP2Ks are activated by upstream MAP3K enzymes through phosphorylation of activation loop serine or threonine residues. MAP3Ks with the capacity to activate JNK/ SAPKs include MEKKs (MEKK1, -2, -3 and -4), mixed lineage kinases (MLKs, including MLK1-3 and DLK), Tpl2, ASKs, TAOs and TAK1 (Kyriakis and Avruch, 2001) . Knockout studies in several organisms indicate that different MAP3Ks predominate in JNK/SAPK activation in response to different upstream stimuli. The wiring may be comparable to, but perhaps even more complex than, MAP3K selection and control of the ERK1/2 pathway (see Johnson article, this volume).
Structural insights and regulation via docking domains
Crystal structures of JNK3a1 bound to adenylylimidodiphosphate (AMP-PNP) and JNK1 complexed with a peptide from the scaffold JNK interacting protein 1 (JIP1) showed overall architecture similar to ERK2 and p38 (Heo et al., 2004) . In the active site cleft, the glycinerich sequence of JNK3 forms a well-defined b-strandturn-b-strand structure over the bound nucleotide. The insertion in the C-terminal domain that is a characteristic of MAPKs is 12 residues longer in JNKs than in ERK2 and p38. This JNK insertion results in the N-terminal extension of helix aH and an extra 3 10 helix in this unique MAPK feature. As with ERK1/2, another mechanism of ensuring signaling specificity and efficiency in the JNK cascade arises from modular interaction sequences. D motifs are found in many JIPs, including MEK4/7, MKPs, scaffold proteins and substrates. c-Jun is perhaps the best known JNK substrate; it has a d-domain acting as the docking sequence for JNK. This docking site was shown to be important for efficient phosphorylation of c-Jun by JNK and for the activity of its transcriptional activation domain (Hibi et al., 1993; Sharrocks et al., 2000) . The D motif promotes interaction of JNK with the MAP3K MEKK1 (Xu and Cobb, 1997) . The N-terminal portion of MEK4 contains a MAPK-docking site and serves as a binding site for both the upstream activator MEKK1 and the downstream target JNK (Xia et al., 1998) . Other MEKKs such as MEKK2 may also interact with multiple components of JNK/SAPK pathways through their own binding sites. JIP1 binds specifically to JNK MAPKs via its docking domain.
Scaffolding molecules of JNK pathways JIP1, also called Islet-brain 1 (IB1) protein, was the first scaffolding protein identified in the JNK module via a yeast two-hybrid screen (Bonny et al., 1998; Whitmarsh et al., 1998) . JIP1 and JIP2 are structurally similar and form homo-and hetero-oligomers with components of the JNK signaling pathway. Both JIP1 and JIP2 strongly potentiate JNK activation by the MLK family, but little evidence supports participation in signaling by the MEKK group of MAP3Ks. APLIP1, a neuronally expressed D. melanogaster homolog of JIP1, was identified in a genetic screen for kinesin heavy chaininteracting proteins, perhaps consistent with earlier studies suggesting that JIPs may move JNKs along axons to growth cones (Kelkar et al., 2000; Horiuchi et al., 2005) .
JIP3 (or JSAP1) and JLP (JNK-associated leucine zipper protein, also known as JIP4) are related but structurally distinct from JIP1/2 (Kelkar et al., 2000) . Similar to JIP1/2, JIP3 interacts with JNK, MEK7 and MLK3. The interaction of JIP3 with MEKK1 and MEK4 has also been described (Ito et al., 1999) . JLP was first reported as a scaffolding protein that binds Max and c-Myc along with JNK and p38 MAPK, and their upstream kinases MEK4 and MEKK3 (Lee et al., 2002) . JLP specifically interacts with G a12 and G a13 but not G a s,i,q (Kashef et al., 2005) . Another JIP4 splice form was identified which binds JNK but does not interact with MEK7 or MLK3; it apparently does not promote activation of the JNK pathway (see below) (Kelkar et al., 2005) . JIP proteins are enriched in certain cell types including b-cells and neurons, suggesting scaffolding by JIPs may be cell-type and context-specific.
Axin is a multidomain scaffold protein originally identified as an inhibitor of the Wnt-signaling pathway. It also activates the JNK pathway by binding to MEKK1 and MEKK4. The domains utilized for Wnt and MEKK1/4 interactions are distinct, making it possible to impact both pathways simultaneously (Zhang et al., 1999; Luo et al., 2003) . Unlike JIPs, axin does not interact with either MEK4/7 or JNK directly. On the basis of earlier studies, MEKK1/4 are presumed to scaffold the downstream kinases. MEKK4 and MEKK1 compete for axin binding, although they bind to sites far apart. This suggests that axin may selectively bind to MEKK1 or MEKK4 depending on distinct signals or cellular context.
Yet another JNK pathway scaffold is the protein plenty of SH3s (POSH), which leads to neuronal cell death in mammalian cells and D. melanogaster. It binds to MLKs, MEK4/7 and JNKs (Tapon et al., 1998; Xu et al., 2003; Tsuda et al., 2006) . POSH has been suggested to cooperate with JIP1. In this model, POSH, JIP1, MLKs, MEK4/7 and JNKs form a multiprotein complex, which has been named PJAC (POSH-JIP apoptotic complex). POSH binds and activates MLKs, which leads in turn to sequential activation of MEK4/7 and JNKs that are recruited to the complex by JIPs.
Phosphatases
To date, the reported JNK phosphatases are the dual-specificity MKPs. MKP-7 and VH5 are JNK phosphatases Differential regulation and properties of MAPKs M Raman et al that also dephosphorylate p38a and -b (Alonso et al., 2004) . Both contain MAPK-binding domains, DSP domains, and a C-terminal PEST sequence (enriched in proline, glutamate, serine and threonine), which suggests that they are rapidly turned over. Other MKPs with some reported activity toward JNKs are DSP2, MKP6, MKP1, MKP2, MKP4 and MKP5 (Alonso et al., 2004) . Though little is known about the phosphatases that act on upstream MAP2Ks and MAP3Ks, the phosphoserine/threonine protein phosphatase 5 (PP5) was reported to suppress hypoxia-induced ASK1/MEK4/JNK signaling. PP5 is an okadaic acid-, microcystin-and calyculin A-sensitive phosphatase that belongs to the PPP phosphoprotein phosphatase family of enzymes (Chinkers, 2001) . Suppression of PP5 expression results in an increase in ASK1 activity. In vitro PP5 can dephosphorylate Thr845, an activation-associated site on ASK1. These findings suggest that PP5 functions to inactivate ASK1 and perhaps other MAP3Ks (Zhou et al., 2004) .
Other post-translational modifications affecting JNK activation JNK activation is also regulated by ubiquitylation. The MAP3K, MEKK1 harbors a C-terminal kinase domain and a large non-catalytic N-terminus. It can activate MEK1 and MEK4 in the ERK1/2 and JNK pathways in response to specific stimuli. A plant homeodomain (PHD) domain resides in the N terminus which harbors E3 ubiquitin ligase activity (Lu et al., 2002) . Activation of MEKK1 not only stimulates its ability to phosphorylate and activate MEK1 and MEK4 in the ERK1/2 and JNK pathways but also leads to the ubiquitylation of MEKK1 itself. This ubiquitylation subsequently inhibits MEKK1-catalysed phosphorylation of MEK1 and MEK4, thereby downregulating the MEKK1 activation of the ERK1/2 and JNK pathways (Witowsky and Johnson, 2003) . MEKK1 E3 activity may also have an impact on JNK substrate stability (Cuevas et al., 2005) .
p38 MAPKs
Introduction p38 was found as a tyrosine-phosphorylated protein in LPS-stimulated macrophages (Chen et al., 2001; Johnson and Lapadat, 2002) . Simultaneously, the human homologs of p38 were cloned as molecules that bound to pyridinyl imidazole compounds. These drugs inhibit interleukin-1 (IL-1) and TNF production from stimulated human monocytes (Lee et al., 1994) . At the same time, p38 was identified as a protein that stimulated MAPKAP kinase-2 (MK2) by cellular stressors. There are four p38 family members (a, b, g and d). p38 MAPKs respond to a wide range of extracellular cues particularly cellular stressors such as UV radiation, osmotic shock, hypoxia, pro-inflammatory cytokines and less often growth factors. Responding to osmotic shock might be viewed as one of the oldest functions of this pathway, because the yeast p38 activates both shortand long-term homeostatic mechanisms to osmotic stress. p38 is activated via dual phosphorylation on the TGY motif within its activation loop by its upstream protein kinases MEK3 and -6. Although p38s share about 40% sequence identity with other MAPKs, they share only about 60% identity among themselves, suggesting highly diverse functions. p38a and -b are ubiquitously expressed and are inhibited by pyridinyl imidazole compounds, whereas expression of p38g and -d appears to be more tissue restricted and these two protein kinases are insensitive to the drugs.
Pharmacological inhibitors have accelerated studies of the two sensitive isoforms. Many conclusions drawn from p38a/b studies are assumed without substantiation to apply to the d/g forms. In PC12 cells, p38g appears to be selectively activated by hypoxia in a calciumdependent manner to negatively regulate cyclin D1 expression (Conrad et al., 1999 (Conrad et al., , 2000 . In NIH-3T3 cells, overexpression of Rho activates p38g specifically in a MEK3-dependent manner (Marinissen et al., 2001) . Several studies have highlighted the role of p38-MK2 activation in the induction of cell-cycle checkpoints following DNA damage (Wang et al., 2000; Bulavin et al., 2001; Manke et al., 2005) . Although most studies have not clearly distinguished which p38 is required for this phenomenon, one study has reported a role for MEK6 and p38g in the activation of the G2/M cell-cycle checkpoint following ionizing radiation (Wang et al., 2000) . p38d appears to be developmentally regulated (Hu et al., 1999) . This isoform specifically phosphorylates stathmin and thus regulates microtubule dynamics (Parker et al., 1998) . More recently, a role for p38d in human keratinocyte differentiation has been observed. Although all p38 family members are expressed in these cells, p38d appears to be specifically activated by novel protein kinase C (nPKC) isoforms in response to 12-O-tetradecanoylphorbol-13-acetate (TPA), okadaic acid and calcium. Activation subsequently increases human involucrin gene expression, which is required for differentiation (Efimova et al., 2002) . In this system, okadaic acid activates p38d and inhibits ERK1/2. p38d and ERK1/2 have also been shown to co-precipitate (Efimova et al., 2003) . Hence, p38d activation inhibits keratinocyte proliferation and drives differentiation. Additionally, the substrate specificities of p38a/b differ from that of p38g/d. Although the a/b isoforms are capable of phosphorylating MK2, p38g/d do not.
The MAP2Ks MEK3 and -6 may both be required for maximal activation of p38. This has been attributed to the selective recognition of individual p38 isoforms by these MAP2Ks. The p38a, -g and -d kinases are phosphorylated by both MEK3 and MEK6. p38b may be preferentially phosphorylated by MEK6 (Enslen et al., 1998) . In vitro MEK4 has also been shown to activate p38, and, in cases in which MEK3 and -6 are limiting or absent, MEK4 may assume the role of activating p38 (Brancho et al., 2003) . MEK3/6 are activated by numerous MAP3Ks including MEKK1-4, TAOs, TAK and ASK, Little is known about how specific ligands utilize p38 (or JNK) to produce varied outputs. Certainly, differential wiring at the level of the MAP3Ks in this pathway will provide much of the needed specificity; yet little progress has been made in parsing out individual contributions from MAP3Ks in the activation of p38.
Activation of p38: structural insights and interaction domains The crystal structure of p38a was originally solved in the unphosphorylated inactive form (Wilson et al., 1996; Wang et al., 1997) . Although the N-and C-terminal folding domains of p38 are structurally similar to those of ERK2 in its inactive form, significant differences are observed in the activation loop. The loop in p38 is smaller by six residues than that in ERK2, and threonine 180 and tyrosine 182 that form the TGY motif are solvent exposed, whereas in ERK2 they are buried. Additionally, residues in the activation loop are oriented in such a manner as to occlude the substratebinding groove. The N-and C-terminal domains of the p38 protein kinase core are rotated away from each other, a characteristic not observed in ERK2. These findings are consistent with the low affinity of p38 for ATP and suggest that significant rearrangement of the domains relative to each other must occur for the protein kinase to adopt an active conformation (Frantz et al., 1998) .
The initial analysis of the structure helped to explain mutagenesis studies that showed that the sequence of the activation loop alone does not specify recognition by upstream protein kinases; elements distant from the activation loop are also involved in recognition and binding. In support of this hypothesis, multiple regions have been identified on MAPKs that mediate specificity of interaction with substrates and regulators. The CD region found in ERK1/2 and JNK protein kinases is also found in p38 isoforms (Tanoue et al., 2000) . Mutations of the acidic residues in the CD region not only decrease binding, but also diminish the efficiency of p38 activation or inhibition. Splice variants of MEK3 and -6 that lack the docking site are less efficient in activating p38, underscoring the importance of these domains in enhancing the efficiency of signaling. In addition to the CD domain, additional motifs have been identified in p38 and ERK2 that regulate interactions with a subset of binding proteins. In p38, glutamate 160 and aspartate 161 (ED site) are required for the interaction of p38 with the MAPKAP group of proteins (Tanoue et al., 2001) .
MAPK binding to activators or substrates via interaction sites such as D motifs may facilitate phosphorylation by causing rearrangement within the protein kinase itself. The crystal structure of p38a in a complex with peptides derived from its activator MEK3 or a substrate MEF2C reveals that binding of these peptides causes significant conformational changes in the activation loop . Both peptides bind to the same region of p38 but cause distinct conformational changes. This suggests that identical domains in protein kinases may be differentially recognized by binding partners to generate distinct outcomes. The position of interaction motifs relative to one another, the distance between motifs and even single amino-acid residues differences in motifs dictate the ability of a MAPK to associate with its substrate (Barsyte-Lovejoy et al., 2002) . The strength of the interactions, based on the individual affinities and the number of interaction sites, will be involved in determining the cellular outcome of activation of multiple MAPK cascades that converge on a single protein.
Scaffolding proteins Surprisingly few scaffolds have been identified for the p38 pathway components in mammalian cells. A scaffold specific for p38 has been identified that functions in sensing osmotic stresses. Osmosensing scaffold for MEKK3 (OSM) binds to MEKK3, MEK3 and p38 (Uhlik et al., 2003) . In response to osmotic stress, OSM binds to Rac at membrane ruffles and recruits the p38 cascade with it. This brings p38 and the other associated kinases in proximity to the actin cytoskeleton, which must be reorganized to allow for adaptation of the cell to osmotic stress.
The JIPs and JSAPs, JNK scaffolds, appear to scaffold members of the p38 MAPK family as well. A number of studies have demonstrated that JIP2 can enhance p38 signaling by binding to p38a and -d. In one study, JIP2 scaffolded the Rac guanine nucleotide exchange factors (GEFs) Tiam1 and Ras-GRF1 to the MAP3K MLK3, the MAP2K MEK3 and p38a (Buchsbaum et al., 2002) . JIP2 binding to p38d is reportedly enhanced by fibroblast growth factor homologous factor 2 (FHF2) (Schoorlemmer and Goldfarb, 2002) . JIP4 is a p38 substrate and enhances activation of p38. It interacts with JNK also, but does not enhance JNK activation; thus, its role in JNK signaling is apparently not to scaffold an activation complex (Kelkar et al., 2005) . On the basis of sequence alone, it is presently unclear why some of these scaffolds bind to p38 as well as to JNK. Perhaps preferential binding of these scaffolds suppresses signaling through one MAPK pathway while enhancing signaling through another. More detailed loss of function experiments with knockout mice or siRNA will be necessary to ascertain the roles of these proteins in the activation of JNK and p38 cascades.
Modulation of signaling by protein phosphatases
Among the DSPs, DSP2, MKP1, MKP5, VH5 and MKP7 appear to target p38 and JNK MAPKs preferentially over ERK1/2. MKP1, known as an immediate early gene, has a demonstrated role in the innate immune response via its ability to regulate LPS responses. Mice deficient in MKP1 are more susceptible to endotoxic shock and display enhanced production of proinflammatory cytokines (Chi et al., 2006) . LPS treatment induces MKP-1 expression, presumably as a feedback mechanism through p38 activation, and subsequent inhibition of p38 and JNK activation by this agent. MKP1-null mice display sustained levels of p38 and JNK activity in response to endotoxic shock, highlighting the role of this phosphatase in regulating cytokine production by modulating MAPK activation (Hu et al., 2006; Salojin et al., 2006) . MKP1-null mice have higher ERK1/2, JNK and p38 activation in insulinresponsive tissues. These mice are lean and resistant to diet-induced obesity, but develop glucose intolerance on a high fat diet . Other p38-specific MKPs include MKP5, MKP7 and MKP8. Not all MKPs bind to MAPKs via the CD site, hence, novel modes of binding and regulation must exist between these phosphatases and the MAPKs they inactivate (Aoyama et al., 2001) . PP2A and PP2B (calcineurin) have also been reported to regulate p38 via targeting of the phosphatase catalytic subunit to the MAPK by regulatory B subunits.
p38 splice variants Two p38 splice variants have been identified that have divergent properties. Mxi2 was initially identified as a protein that bound to and phosphorylated the nuclear protein Max (Zervos et al., 1995) . Subsequently, it was found to be a splice variant of p38a that is identical in sequence to p38a between residues 1 and 280 but lacks the CD site found in p38. Mxi2 also has an extra 17 residues in its C-terminus that are not found in p38. The protein appears to be localized to the distal portion of the nephron with little protein expression in other cell types (Faccio et al., 2000) . Despite the high sequence identity between the two proteins, they are regulated in a distinct manner. Mxi2 is not activated by well-studied p38 agonists such as UV and TNFa for example. It is activated to some extent by lysophosphatidic acid (LPA) and EGF. In addition it appears to be insensitive to activation by MEK3 and -6 and does not phosphorylate known p38 substrates such as ATF2 and MEF2C, ostensibly because of the lack of a CD domain. Despite the conservation of the ATP-binding pocket and activation loop, Mxi2 is less sensitive to SB203580 inhibition (Faccio et al., 2000; Sanz et al., 2000) . Mxi2 was discovered to bind to ERK1/2 via its unique C-terminus and sustain ERK1/2 activation in the nucleus. This activation was independent of Mxi2 kinase activity and may involve protection of ERK1/2 against phosphatases that downregulate ERK1/2 activity. Because of the restricted expression pattern of Mxi2, this interaction appears to be cell-type and contextspecific (Sanz-Moreno et al., 2003) . This finding parallels a previous finding of direct interactions between p38 and ERK1/2. Stress-induced activation of p38 enhanced its binding to ERK1/2 and inhibited ERK1/2-dependent signaling, possibly by sequestering ERK1/2 from upstream kinases (Zhang et al., 2001) .
Another splice variant of p38a is exon-skip (Exip). Exip is very similar to Mxi2 in that it shares complete identity with p38a in the first 250 amino acids. Owing to alternative splicing Exip lacks the CD site and instead has a unique 53 amino-acid C-terminal region not found in p38. Initial studies found that overexpressed Exip initiates apoptosis in HeLa cells (Sudo et al., 2002) . Exip is reported to bind to Toll-interacting protein (Tollip) and IL-1-associated kinase (IRAK). Overexpression of Exip marginally impairs NF-kB activation by IL-1b (Yagasaki et al., 2004) .
Regulation of cellular localization
Much effort has been invested in understanding the regulation of nuclear translocation of ERK1/2 in response to stimuli. Despite the fact that ERK1/2, JNK and p38 share a large number of common substrates, the same depth of knowledge in mechanisms of p38 and JNK localization is lacking. Members of both kinase groups are found in the nucleus, consistent with the large number of transcription factors phosphorylated by them. In 293T cells, it has been reported that p38 is nuclear in resting cells and is exported to the cytosol following stimulation by a number of agents. This pattern of localization mirrors that of the p38 substrate MK2. Phosphorylation of MK2 by p38 within the nucleus causes export of the p38-MK2 complex, presumably to allow these kinases to phosphorylate cytosolic targets (Ben-Levy et al., 1998) . Similar effects have been observed with p38 and MK5 (Seternes et al., 2002) . In NIH-3T3 cells, ERK1/2 nuclear localization is anchorage-dependent, whereas the localization of JNK and p38 to the nucleus occurs irrespective of adhesion (Aplin et al., 2002) . There is likely to be isoform-specific localization of p38 family members; in cultured cardiac myocytes, p38g is localized to cytosolic foci in a manner insensitive to leptomycin B, an inhibitor of nuclear export by the export protein CRM1. In the same cells p38a/b are both cytosolic and nuclear and can be trapped in the nucleus with leptomycin B (Court et al., 2002) . The localization of p38a appears to be modulated by the TAK1-binding protein 1 (TAB1) which can induce p38 activation in a MEK-independent manner. TAB1 has been shown to compete with MEK3 for binding to p38 and inhibits MEK3-dependent downstream signaling. Although activated MEK3 enhances nuclear levels of p38, TAB1 has the opposite effect and causes the redistribution of p38 to the cytosol (Lu et al., 2006) . NESs have been identified and well characterized in MEK1/2; no such sequences have been identified in MEK3 and 6. Thus, the functions of MEK3/ 6 in regulating p38 localization are unclear. p38 plays a role in multiple stress-sensitive pathways, hence, it is highly likely that this protein kinase localizes to discrete areas in the cell to efficiently engage its targets. The presence of multiple isoforms and splice forms has slowed elucidation of mechanisms underlying localization and the impact of localization on downstream signaling.
Gene names
(ERK2 ¼ MAPK1; ERK1¼ MAPK3; ERK5¼ MAPK7; JNK1 ¼ MAPK8; JNK2¼ MAPK9; JNK3 ¼ MAPK10; p38a ¼ MAPK14; p38b ¼ MAPK11; p38d ¼ MAPK13; p38g ¼ MAPK12).
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